Sept 11 (Reuters) – The U.S. Food and Drug Administration approved Scholar Rock’s therapy on Friday to treat a rare genetic condition that causes muscle weakness.
The therapy, sold as Isembyld, is the first muscle-targeted therapy designed to improve motor function for adults and children with spinal muscular atrophy who have been treated with existing therapies for the condition.
Scholar Rock shares were halted in aftermarket trading.
Spinal muscular atrophy is a genetic disorder that affects motor neurons, the nerve cells that control voluntary muscle movement. It causes progressive weakness in the arms and legs and difficulty walking, breathing or swallowing.
The condition is estimated to affect roughly 10,000 children and adults in the United States, according to the Muscular Dystrophy Association.
(Reporting by Sneha S K and Christy Santhosh in Bengaluru; Editing by Tasim Zahid)
Comments